TORPEdO: A phase III trial of intensity-modulated proton beam therapy versus intensity-modulated radiotherapy for multi-toxicity reduction in oropharyngeal cancer.


Journal

Clinical and translational radiation oncology
ISSN: 2405-6308
Titre abrégé: Clin Transl Radiat Oncol
Pays: Ireland
ID NLM: 101713416

Informations de publication

Date de publication:
Jan 2023
Historique:
received: 17 10 2022
accepted: 18 11 2022
entrez: 1 12 2022
pubmed: 2 12 2022
medline: 2 12 2022
Statut: epublish

Résumé

•There is a lack of prospective level I evidence for the use of PBT for most adult cancers including oropharyngeal squamous cell carcinoma (OPSCC).•TORPEdO is the UK's first PBT clinical trial and aims to determine the benefits of PBT for OPSCC.•Training and support has been provided before and during the trial to reduce variations of contouring and radiotherapy planning.•There is a strong translational component within TORPEdO. Imaging and physics data along with blood, tissue collection will inform future studies in refining patient selection for IMPT.

Identifiants

pubmed: 36452431
doi: 10.1016/j.ctro.2022.11.010
pii: S2405-6308(22)00109-4
pmc: PMC9702982
doi:

Types de publication

Journal Article

Langues

eng

Pagination

147-154

Informations de copyright

© 2022 The Authors.

Déclaration de conflit d'intérêts

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Références

Oral Oncol. 2011 Mar;47(3):180-4
pubmed: 21227737
Clin Transl Radiat Oncol. 2019 Jul 12;19:17-26
pubmed: 31372521
Oral Oncol. 2014 Dec;50(12):1182-7
pubmed: 25448227
Lancet Oncol. 2011 Feb;12(2):127-36
pubmed: 21236730
Radiother Oncol. 2016 Jul;120(1):48-55
pubmed: 27342249
J Laryngol Otol. 2016 May;130(S2):S90-S96
pubmed: 27841123
Clin Oncol (R Coll Radiol). 2018 May;30(5):277-279
pubmed: 29530438
Clin Oncol (R Coll Radiol). 2018 May;30(5):271-273
pubmed: 29239732
Cancer. 1990 Aug 1;66(3):564-9
pubmed: 2364368
Radiother Oncol. 2013 Jun;107(3):267-73
pubmed: 23759662
Clin Oncol (R Coll Radiol). 2018 May;30(5):280-284
pubmed: 29551566
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Int J Radiat Oncol Biol Phys. 2019 Jul 1;104(3):553-562
pubmed: 30625409
Radiother Oncol. 2018 Jan;126(1):56-67
pubmed: 28943045
J Clin Oncol. 2008 Aug 1;26(22):3770-6
pubmed: 18669465
Clin Oncol (R Coll Radiol). 2020 Feb;32(2):84-88
pubmed: 31604604

Auteurs

David J Thomson (DJ)

The Christie NHS Foundation Trust, Manchester, United Kingdom.

Clare Cruickshank (C)

The Institute of Cancer Research, London, United Kingdom.

Helen Baines (H)

Radiotherapy Trials QA Group (RTTQA), The Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom.

Russell Banner (R)

Swansea Bay University Health Board, Swansea, United Kingdom.

Matthew Beasley (M)

Bristol Cancer Institute, Bristol, United Kingdom.

Guy Betts (G)

Manchester University NHS Foundation Trust. Manchester, United Kingdom.

Helen Bulbeck (H)

Brainstrust - The Brain Cancer People, Cowes, United Kingdom.

Frances Charlwood (F)

The Christie NHS Foundation Trust, Manchester, United Kingdom.

Judith Christian (J)

Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom.

Matthew Clarke (M)

The Christie NHS Foundation Trust, Manchester, United Kingdom.

Olly Donnelly (O)

Portsmouth Hospitals NHS Trust, Portsmouth, United Kingdom.

Bernadette Foran (B)

Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, United Kingdom.

Callum Gillies (C)

University College Hospitals London NHS Foundation Trust, London, United Kingdom.

Clare Griffin (C)

The Institute of Cancer Research, London, United Kingdom.

Jarrod J Homer (JJ)

Manchester University NHS Foundation Trust. Manchester, United Kingdom.

Johannes A Langendijk (JA)

University Medical Centre Groningen, University of Groningen, Groningen, the Netherlands.

Lip Wai Lee (LW)

The Christie NHS Foundation Trust, Manchester, United Kingdom.

James Lester (J)

Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, United Kingdom.

Matthew Lowe (M)

The Christie NHS Foundation Trust, Manchester, United Kingdom.

Andrew McPartlin (A)

Princess Margaret Hospital, Toronto, Canada.

Elizabeth Miles (E)

Radiotherapy Trials QA Group (RTTQA), Mount Vernon Hospital, Northwood, United Kingdom.

Christopher Nutting (C)

The Institute of Cancer Research, London, United Kingdom.
The Royal Marsden NHS Foundation Trust, London, United Kingdom.

Nachi Palaniappan (N)

Velindre NHS Trust, Cardiff, United Kingdom.

Robin Prestwich (R)

The Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom.

James M Price (JM)

The Christie NHS Foundation Trust, Manchester, United Kingdom.
The University of Manchester, Manchester, United Kingdom.

Clare Roberts (C)

The Christie NHS Foundation Trust, Manchester, United Kingdom.

Justin Roe (J)

The Royal Marsden NHS Foundation Trust, London, United Kingdom.
Imperial College, London, United Kingdom.

Ramkumar Shanmugasundaram (R)

University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom.

Rita Simões (R)

Radiotherapy Trials QA Group (RTTQA), Mount Vernon Hospital, Northwood, United Kingdom.

Anna Thompson (A)

University College Hospitals London NHS Foundation Trust, London, United Kingdom.

Catharine West (C)

The University of Manchester, Manchester, United Kingdom.

Lorna Wilson (L)

The Christie NHS Foundation Trust, Manchester, United Kingdom.

Jane Wolstenholme (J)

Health Economics Research Centre, University of Oxford, United Kingdom.

Emma Hall (E)

The Institute of Cancer Research, London, United Kingdom.

Classifications MeSH